240 related articles for article (PubMed ID: 26303047)
21. Endotherapy for and tailored approaches to treating GERD, and refractory GERD.
Locke GR; Horwhat J; Mashimo H; Savarino E; Zentilin P; Savarino V; Zerbib F; Armbruster SP; Wong RK; Moawad F
Ann N Y Acad Sci; 2013 Oct; 1300():166-186. PubMed ID: 24117641
[TBL] [Abstract][Full Text] [Related]
22. Weakly acidic reflux.
Tack J; Blondeau K
Dig Dis; 2009; 27(1):58-61. PubMed ID: 19439962
[TBL] [Abstract][Full Text] [Related]
23. Sleep disturbances and refractory gastroesophageal reflux disease symptoms in patients receiving once-daily proton pump inhibitors and efficacy of twice-daily rabeprazole treatment.
Fujiwara Y; Habu Y; Ashida K; Kusano M; Higuchi K; Arakawa T
Digestion; 2013; 88(3):145-52. PubMed ID: 24008338
[TBL] [Abstract][Full Text] [Related]
24. The early therapeutic response at 2 weeks is a crucial predictor of proton pump inhibitor-refractory gastroesophageal reflux disease.
Ogawa M; Arihiro S; Matsuhashi N; Joh T; Higuchi K; Iwakiri K; Kamiya T; Manabe N; Isshi K; Nakada T; Hokari A; Saruta M; Oshio A; Haruma K; Nakada K
Esophagus; 2021 Apr; 18(2):398-406. PubMed ID: 33136239
[TBL] [Abstract][Full Text] [Related]
25. Esophageal pH-impedance monitoring in patients with therapy-resistant reflux symptoms: 'on' or 'off' proton pump inhibitor?
Hemmink GJ; Bredenoord AJ; Weusten BL; Monkelbaan JF; Timmer R; Smout AJ
Am J Gastroenterol; 2008 Oct; 103(10):2446-53. PubMed ID: 18684197
[TBL] [Abstract][Full Text] [Related]
26. Voluntary and controlled weight loss can reduce symptoms and proton pump inhibitor use and dosage in patients with gastroesophageal reflux disease: a comparative study.
de Bortoli N; Guidi G; Martinucci I; Savarino E; Imam H; Bertani L; Russo S; Franchi R; Macchia L; Furnari M; Ceccarelli L; Savarino V; Marchi S
Dis Esophagus; 2016; 29(2):197-204. PubMed ID: 25516110
[TBL] [Abstract][Full Text] [Related]
27. Maintenance treatment with proton pump inhibitors for reflux esophagitis in pediatric patients: a systematic literature analysis.
Illueca M; Wernersson B; Henderson C; Lundborg P
J Pediatr Gastroenterol Nutr; 2010 Dec; 51(6):733-40. PubMed ID: 20808247
[TBL] [Abstract][Full Text] [Related]
28. Increased proximal reflux in a hypersensitive esophagus might explain symptoms resistant to proton pump inhibitors in patients with gastroesophageal reflux disease.
Rohof WO; Bennink RJ; de Jonge H; Boeckxstaens GE
Clin Gastroenterol Hepatol; 2014 Oct; 12(10):1647-55. PubMed ID: 24184737
[TBL] [Abstract][Full Text] [Related]
29. Diagnostic work-up of GERD.
Vela MF
Gastrointest Endosc Clin N Am; 2014 Oct; 24(4):655-66. PubMed ID: 25216910
[TBL] [Abstract][Full Text] [Related]
30. Addition of prokinetics to PPI therapy in gastroesophageal reflux disease: a meta-analysis.
Ren LH; Chen WX; Qian LJ; Li S; Gu M; Shi RH
World J Gastroenterol; 2014 Mar; 20(9):2412-9. PubMed ID: 24605040
[TBL] [Abstract][Full Text] [Related]
31. Clinical symptoms of FSSG in gastroesophageal reflux disease are critical for PPI treatment: Japanese multi-centers with 185 patients.
Komatsu-Tanaka M; Iwakiri R; Fujimoto K; Fujiwara Y; Inamori M; Tanaka J; Shimatani T; Akiyama J; Ando T; Manabe N; Kinjo F; Deguchi R; Kusano M
Dig Endosc; 2012 Nov; 24(6):407-11. PubMed ID: 23078431
[TBL] [Abstract][Full Text] [Related]
32. Diagnosis and management of patients with reflux symptoms refractory to proton pump inhibitors.
Sifrim D; Zerbib F
Gut; 2012 Sep; 61(9):1340-54. PubMed ID: 22684483
[TBL] [Abstract][Full Text] [Related]
33. Lower pH values of weakly acidic refluxes as determinants of heartburn perception in gastroesophageal reflux disease patients with normal esophageal acid exposure.
de Bortoli N; Martinucci I; Savarino E; Franchi R; Bertani L; Russo S; Ceccarelli L; Costa F; Bellini M; Blandizzi C; Savarino V; Marchi S
Dis Esophagus; 2016 Jan; 29(1):3-9. PubMed ID: 25212408
[TBL] [Abstract][Full Text] [Related]
34. Comparative outcomes of antireflux treatment for laryngopharyngeal reflux symptoms and upper abdominal symptoms in patients with endoscopic esophagitis.
Toros AB; Toros SZ; Ozel L; Ersoz F; Saglam M; Sametoglu F
Eur Arch Otorhinolaryngol; 2011 May; 268(5):703-8. PubMed ID: 21170720
[TBL] [Abstract][Full Text] [Related]
35. Twice-daily proton pump inhibitor therapy does not decrease the frequency of reflux episodes during nocturnal recumbency in patients with refractory GERD: analysis of 200 patients using multichannel intraluminal impedance-pH testing.
Clayton SB; Rife CC; Singh ER; Kalbfleisch JH; Castell DO
Dis Esophagus; 2012; 25(8):682-6. PubMed ID: 22292567
[TBL] [Abstract][Full Text] [Related]
36. The evolution of proton pump inhibitors for the treatment of gastroesophageal reflux disease.
Friedlander EA; Pallentino J; Miller SK; VanBeuge SS
J Am Acad Nurse Pract; 2010 Dec; 22(12):674-83. PubMed ID: 21129076
[TBL] [Abstract][Full Text] [Related]
37. Eosinophilic esophagitis in GERD patients: a clinicopathological diagnosis using proton pump inhibitors.
Molina-Infante J; Ferrando-Lamana L; Fernandez-Bermejo M; Porcel-Carreño S
Am J Gastroenterol; 2009 Nov; 104(11):2856-7. PubMed ID: 19888246
[No Abstract] [Full Text] [Related]
38. Rapid metabolizer genotype of CYP2C19 is a risk factor of being refractory to proton pump inhibitor therapy for reflux esophagitis.
Ichikawa H; Sugimoto M; Sugimoto K; Andoh A; Furuta T
J Gastroenterol Hepatol; 2016 Apr; 31(4):716-26. PubMed ID: 26580676
[TBL] [Abstract][Full Text] [Related]
39. Proton pump inhibitors in the management of gastroesophageal reflux disease.
Hrelja N; Zerem E
Med Arh; 2011; 65(1):52-5. PubMed ID: 21534455
[TBL] [Abstract][Full Text] [Related]
40. Management strategies for gastroesophageal reflux disease.
Bak YT
J Gastroenterol Hepatol; 2004 Sep; 19 Suppl 3():S49-53. PubMed ID: 15324382
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
